Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

A trial testing the combination of the anti-TIGIT antibody tiragolumab and atezolizumab vs atezolizumab in previously untreated programmed cell death ligand 1 (PD-L1)–high locally advanced ...

KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, ...

Patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation experienced ...

A post hoc analysis shows significantly improved ORR and PFS in advanced NSCLC with higher AFM24 exposure, supporting ...

A panelist discusses how the MARIPOSA, SKIPPirr, and COCOON studies highlight the significant overall survival benefit of the ...

DelveInsight's data-driven approach not only illuminated the path forward but also positioned the client as a frontrunner in biomarker-driven NSCLC therapies. This case study showcases how ...